EPIPACE was created by a cardiac electrophysiologist who spent years implanting pacemakers and witnessing the limitations of conventional pacing—especially in children who may require lifelong treatment
Early in my electrophysiology practice, I implanted pacemakers in patients of many different ages. One of those patients was a 20-day-old infant with congenital complete heart block.
Her heart was extraordinarily small compared with the pacemaker system and the wire that had to be placed within it. Seeing the size of the hardware relative to such a tiny heart was deeply striking. I remember thinking that there had to be a better solution—something smaller, more appropriate for a child, and less burdensome to the heart it was intended to protect.
That experience became the beginning of the idea that ultimately developed into EPIPACE

A miniature implantable device designed to reduce the physical burden of conventional pacing hardware
An architecture intended to avoid conventional transvenous wires within the veins and cardiac chambers
A platform developed with the long-term needs of children, younger patients, and patients requiring lifelong pacing in mind
EPIPACE emerged from the intersection of clinical experience, pediatric need, electrophysiology, and device innovation. The objective was not simply to modify an existing pacemaker, but to reconsider where a pacemaker should be placed, how it should be powered, and how it could support the heart over decades of treatment
Professor of Cardiology • Electrophysiologist • Medical-Device Inventor
Dr. Olga Bockeria is a cardiologist and cardiac electrophysiologist with extensive experience in the diagnosis and treatment of cardiac arrhythmias, pacemaker therapy, cardiac-safety evaluation, and cardiovascular clinical research.
She currently serves as Senior Cardiologist and Core Lab Director in Cardiac Safety at Clario, part of Thermo Fisher Scientific. In this role, she contributes to the centralized evaluation of cardiac-safety and efficacy endpoints in global clinical trials, including ECG, arrhythmia, ambulatory monitoring, and cardiovascular assessments performed according to rigorous clinical and regulatory standards.
Her combined experience in electrophysiology, cardiac-device therapy, clinical trials, and cardiac-safety operations provides EPIPACE with direct expertise in clinical development, cardiac endpoint assessment, data quality, and the standards required to evaluate cardiovascular technologies.

EPIPACE is supported by an engineering team capable of translating the patented concept into a medical-device development program in accordance with applicable engineering, quality, testing, and regulatory standards.
Development priorities include device miniaturization, epicardial fixation, sensing and pacing performance, energy-harvesting optimization, biocompatibility, durability, manufacturing feasibility, and verification and validation.
The clinical problem defined the invention.
Engineering transforms it into a practical medical-device platform
The vision behind EPIPACE is simple: patients—especially children—should not spend a lifetime adapting to the limitations of the device that was intended to protect them.
EPIPACE is being developed to create a smaller, leadless, epicardial pacing platform designed for longevity, reduced hardware burden, and future expansion into more physiologic cardiac activation
Dr. Bockeria’s current employment is disclosed for biographical purposes only. EPIPACE is an independent invention and venture and is not affiliated with, sponsored by, or developed on behalf of Clario or Thermo Fisher Scientific
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.